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Acute respiratory distress yndrome continues to be associated with significant 
morbidity and mortality related to ventilation-perfusion mismatch, pulmonary 
hypertension, and right ventricular failure. It has been suggested that inhaled 
nitric oxide, which is a selective pulmonary vasodilator, may be effective in the 
treatment ofacute respiratory distress yndrome; however, the etfects of nitric 
oxide on cardiopulmonary interactions are poorly understood. We therefore 
developed a model of acute lung injury that mimics the clinical syndrome of 
acute respiratory distress syndrome. In our model, inhaled nitric oxide 
significantly reduced pulmonary artery pressure, pulmonary vascular esis- 
tance, and pulmonary vascular impedance. In addition, inhaled nitric oxide 
improved transpulmonary vascular efficiency and ventilation-perfusion match- 
ing, which resulted in increased arterial oxygen tension. Although arterial 
oxygen tension increased, oxygen delivery did not improve significantly. 
These data suggest hat by improving ventilation-perfusion matching and 
arterial oxygen tension while lowering pulmonary vascular esistance and 
impedance, nitric oxide may be beneficial in patients with acute respiratory 
distress syndrome. However, additional measures to enhance cardiac 
performance may be required. (J THORAC CARDIOVASC SURG 1995;110: 
593-600) 
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D espite improved understanding of the patho- 
physiology of acute respiratory distress syn- 
drome (ARDS), as well as improvements in diagno- 
sis and supportive care, morbidity and mortality 
from ARDS remain high. 1' 2 ARDS is characterized 
by alveolar membrane damage, depletion of pulmo- 
nary surfactant resulting in decreased lung compli- 
ance, ventilation-perfusion mismatch, and arterial 
hypoxemia. 3 Arterial hypoxia leads to acute pulmo- 
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Table I. Cardiopulmonary measurements before and after lung &vage 
Pao2/Fio2* PPA* Qp~* PVR* TVE* TP* Zo* 
(ton') (mmHg) (tal~min) (dyne . sec~cm 5) (ml/min/mW) (rnW) (dyne .sec~cm s) 
Normal ung 410 -+ 26 15.4 ± 1.3 1313 + 86 1034 -+ 109 25.0 - 0.2 52.6 + 4.9 157 ± 14.7 
Injured lung 190 + 20 24.9 _+ 1.2 1089 + 72 1968 -+ 139 15.4 -+ 0.2 70.8 _+ 5.4 205 ± 13.2 
PaoJFio» Intrapulmonary shunt ratio; PeA, pulmonary artery pressure; Q»4 pulmonary blood flow; PVR, pulrnonary vascular resistance; TP, RV total power; 
TVE, transpulmonary vascular efficiency; Zo, characteristic impedance. 
*p < 0.05 versus normal lung. 
nary artery (PA) hypertension as a result of puP 
monary vasoconstriction and diffuse microvascular 
thrombosis J  The acute elevation of PA  pressure 
increases right ventricular (RV) work requirements 
and can subsequently result in acute RV failure. 
Inhaled nitric oxide (NO) has been shown to reverse 
hypoxic pulmonary vasoconstriction i  larnbs, 5 dogs, 6 
adults, 7 and in pediatric patients with congenital 
heart disease. 8' 9 
Inhaled NO may be efficacious in ARDS,  but its 
effects on ventilation-perfusion matching, transpul- 
monary vascular efficiency, and RV hydraulic power 
are poorly understood. We hypothesized that by 
reducing hypoxic pulmonary vasoconstriction, NO 
would improve cardiopulrnonary interactions during 
ARDS.  The purpose of  this study was to determine 
the effects of NO on ventilation-perfusion matching, 
transpulmonary vascular efficiency, and RV function 
during ARDS.  
Materials and methods 
Fourteen swine were premedicated with acepromazine 
(1.1 mg/kg) and ketamine (22 mg/kg). The animals were 
tracheally intubated, and assisted ventilation was begun 
with a Siemens Servo 300 ventilator (Siemens, Solna, 
Sweden) in the volume control mode. The inspired oxygen 
fraction (Fioz) was set to achieve an arterial oxygen 
tension (Pao2) of more than 60 torr, and the respiratory 
rate was adjusted to maintain an arterial carbon dioxide 
tension (Paco;) of 35 to 45 torr. Anesthesia was main- 
tained throughout he study period by a continuous 
infusion of fentanyl. Intermittent boluses of pancuronium 
were used for paralysis. The animals were heparinized, 
given an intravenous bolus of indomethacin (1ml/kg), and 
then given a continuous drip (indomethacin 0.5 tal/kg per 
250 ml normal saline solution) to block thromboxane- 
mediated vasoconstriction. 
A catheter was placed in the femoral artery to contin- 
uously monitor mean arterial pressure and obtain arterial 
blood gas samples. After a median sternotomy, the peri- 
cardium was incised and fashioned into a pericardial 
cradle. An ultrasonic flow probe (Transonic Systems Inc., 
Ithaca, N.Y.) was placed around the PA at the level of the 
RV outflow tract. Millar pressure catheters (Millar Instru- 
ments, Inc., Houston, Tex.) were passed through subcu- 
taneously tunneled introducer sheaths and placed in the 
PA (at the level of the flow probe), RV, and left atrium. A 
fourth pressure catheter was placed into an introducer 
sheath and positioned in the thoracic avity at the level of 
the left atrium. A chest ube was positioned in the thoracic 
cavity, and atrial pacing wires were sutured to the right 
atrium. A fluid-filled pouch was positioned at the junction 
of the right atrium and superior vena cava and connected 
to a roller pump to maintain continuous cooling of the 
sinoatrial hode and suppress tachycardias. The chest and 
skin were then closed, all air leaks were sealed, and the 
chest tube was placed on water seal. 
Lung injury. Before lung injury, a baseline data set was 
obtained. ARDS was induced by a modification of the 
method of bronchoalveolar lavage described by Lach- 
mann, Robertson, and Vogel. m Each animal was sub- 
jected to lavage with 10 ml warm saline solution per 
kilogram of body weight. Saline solution was introduced 
by a syringe into the endotracheal tube and then removed 
by endotracheal suctioning. After each lavage, the animal 
was subjected to mechanical ventilation for 5 minutes and 
its hemodynamic condition was permitted to stabilize. 
Lavage was repeated until ARDS was created. ARDS was 
defined as a 20% decrease in lung compliance, an alveo- 
lar-arterial gradient greater than 200 witb the ani- 
mal breathing 100% oxygen, and a 50% increase in PA 
pressure. Once these parameters were achieved, volume- 
controlled ventilation was begun at an Fio 2 set to maintain 
the Pao 2 between 60 and 120 torr, a respiratory rate to 
maintain the Paco 2 between 35 and 45 torr, and a positive 
end- expiratory pressure of 3 mm Hg. The eondition of 
the animals was stabilized for 30 minutes before data 
acquisition. Ventilatory settings were then held constant 
throughout the study. 
The swine hearts were atrially paced at a rate of 150 
beats/min during data acquisition to allow for precise 
analysis of pulmonary impedance and RV power indices. 
After the development of ARDS, a baseline data set was 
obtained. NO (NO 777 ppm and NO; < 0.1 ppm, 
National Specialty Gases, Durham, N.C.) was continu- 
ously blended into the inspiratory circuit of the ventilator. 
NO was then administered in a nonrandomized sequential 
fashion with inhaled NO levels of 10, 20, 40, and 80 ppm. 
After the 80 ppm dose of NO, seven animals were 
returned to an NO level of 0 ppm. At each incremental 
change of NO, the animal's condition was permitted to 
stabilize for 5 minutes before data acquisition. The NO 
level of the inspired gas was measured by continuous 
chemiluminescent analysis (model 421-I, Thermo Environ- 
mental Instruments, Inc., Franklin, Mass.). 
Pulmonary vascular mechanics and transpulmonary 
vascular eIfieieney. Data sets were separated into respi- 
ratory cycles and waveforms averaged to calculate the 
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Table II. Cardiorespiratory measurements during NO administration 
NO concentration 
0 ppm 10 ppm 20 ppm 40 ppm 80 ppm 0 ppm (n = 7) 
PPA (mm Hg) 24.9 -- 1.2 20.5 -- 0.7* 20.3 _+ 0.7* 20.3 _+ 0.8* 19.6 _+ 1.0" 27.3 + 1.1 
QPA (tal/min) 1089.2 -+ 72.2 1074.7 -+ 85.9 1026.6 -+ 71.3 1003.1 -- 66.1 1004.5 + 83.3 1018.3 _+ 82.5 
PVR (dyne • sec/cm s) 1968.3 _4- 139.9 1689.5 ___115.6" 1733.3 + 114.1' 1770.0 _+ 104.5" 1720.0 _+ 107.1" 2013.1 - 106.6 
Zo (dyne • sec/cm 5) 205.2 _+ 13.2 183.0 _+ 10.6 184.0 _+ 9.8 187.3 _+ 11.1 184.4 + 15.1 197.3 _+ 12.3 
TP (mW) 70.8 --- 5.4 59.4 + 4.8* 56.6 _+ 4.3* 56.3 _+ 4.6* 53.7 _+ 5.0* 72.3 + 4.5 
SP (mW) 60.2 _+ 4.8 48.9 _+ 4.0* 46.1 _+ 3.5*? 45.6 + 3.7*? 44.0 _+ 4.5"~ 59.7 +_ 4.3 
OP (mW) 10.6 +- 1.5 10.5 +_ 1.7 10.5 _+ 1.8 10.8 _+ 1.6 9.7 +_ 1.1 12.6 _+ 1.5 
TVE (ml/min/mW) 15.4 _+ 0.2 18.2 _+ 0.1" 18.2 +_ 0.1" 17.7 +_ 0.1" 18.8 _+ 0.2* 14.1 _+ 0.2 
MAP (mm Hg) 56.3 +_ 3.4 57.3 + 4.7 56.0 _+ 4.1 55.7 _+ 3.6 54.6 _+ 3.8 57.3 +_ 3.9 
Pao 2 (torr) 98.2 +_ 4.5 127.7 _+ 10.3" 131.9 _+ 12.2" 132.5 _+ 15.6" 131.8 +_ 15.9" 96.1 _+ 14.5 
Pao2/Fioa (torf) 190 _+ 20 240 _+ 20* 250 _+ 30* 250 -- 30* 260 _+ 20* 188 _+ 20 
Do 2 (dl/min) 138 _+ 9 144 _+ 8 141 _+ 10 126 _+ 8 127 + 13 132 +_ 11 
PPA, Pulm°nary artery pressure; Q»A, pulmonary blood flow; PVR, pulmonary vascular resistance; Zo, characteristic impedance; TP, RV total power; SP, RV 
steady power; OP, RV oscillatory power; TVE, transpulmonary vascular elfi iency; MAP, mean arterial pressure; Pao»arterial oxygen content; Pao2/Fio» 
intrapulmonary shunt ratio; Doz, oxygen delivery. 
*p < 0.05 versus 0 ppm. 
?p < 0.05 versus 10 ppm. 
impedance spectrum for that data set. 11 Characteristic 
impedance wa,s derived from the impedance spectrum. 
Total RV hydraulic power was calculated (Zo × QFA 2, 
where Zo is characteristic impedance and QeA is pulmo- 
nary blood flow). It was differentiated into components of
steady power (energy required to move blood forward) 
plus oscillatory power (wasted energy to move blood in an 
oscillatory fashion during pulsatile blood flow). Transpul- 
monary vascular efficiency, a measure of hemodynamic 
supply (blood flow) and demand (total RV power), was 
defined as QeA/total RV power. 
Data analysis. Each data set consisted of pressure and 
flow waveforms sampled at 500 Hz for 50 seconds and stored 
on a 286-based personal computer. Measurements included 
pulmonary blood flow and the following pressures: RV, PA, 
left atrial, intrathoracic cavity, and tracheal. 
Arterial blood gases were obtained at each measure- 
ment period and Pao2/Fio2 ratios were calculated. Calcu- 
lations included the following: pulmonary vascular esis- 
tance ([mean PA pressure - mean LA pressure]/QeA) 
and oxygen delivery (QPA X [Hgb × Sao 2 × 1.34] + 
[Pao 2 × 0.003]), where LA pressure is left atrial pressure, 
Hgb is hem0globin , and Sao2 is arterial oxygen saturation. 
After lung injury, a comparison of the change in measured 
parameters between baseline and subsequent levels of NO 
was performed by a two-way analysis of variance for 
repeated measures. Prelavage and postlavage values were 
compared i n a similar fashion. Ap value less than 0.05 was 
considered; significant. Measurements are reported as 
mean values + standard error of the mean. 
Results 
Etfects o f  ARDS on cardiopulmonary interac- 
tions. Results from the 14 animals before and after 
lung lavage are snmmarized in Table I. 
The animals received an verage of six lavages 
(range two to eight) to achieve lung injury. Ventila- 
tion-peffusion matching decreased (410 _+ 20 versus 
190 + 20 torr, p = 0.001), and PA pressure increased 
(15.4 +_ 3 to 24.5 -+ 1.2 mm Hg, p = 0.001) after lung 
lavage. There was a significant reduction in cardiac 
output (1313 _+ 109 versus 1089 _+ 72 ml/min, p = 
0.007). Lung lavage resulted in a significant increase in 
pulmonary vascular resistance (1034 _+ 109 versus 
1968 _+ 139 dyne • sec/cm 5,p = 0.0001), total RV 
power (52.6 ± 4.9 versus 70.8 _+ 5.4, p = 0.01), and 
characteristic impedance (157 _+ 14.7 versus 205.2 ± 
13.2, p = 0.047). A reduction in transpulmonary 
vascular elticiency (25.0 ± 0.2 versus 15.4 + 0.2 
mW/ml per minute, p = 0.001) also occurred, demon- 
strating less efficient blood flow through the pulmo- 
nary vascular bed. At necropsy, gross pathologic exam- 
ination revealed atelectatic, hemorrhagic, edematous 
lungs with peripheral vascular thrombosis. 
Etfeet of NO on gas exchange. The effects of NO 
on cardiopulmonary measurements are summarized 
in Table II. Inhalation of NO resulted in improved 
oxygenation (Fig. 1). A significant increase in Pao2/ 
Fio2 ratio occurred, from 190 ± 20 to 240 ± 20 torr 
(p = 0.001), when NO was administered in a dose of 
10 ppm. Improvements in ventilation-perfusion 
matching were maintained throughout NO adminis- 
tration, and no dose-response r lationship was seen. 
No significant change in Paco 2 occurred during the 
study. After inhaled NO was discontinued, ventila- 
tion-perfusion matching returned to baseline values. 
Et[ect of NO on pulmonary vascular mechanics. 
Administration of a 10 ppm dose of NO resulted in 
a significant reduction in PA pressure (24.9 + 1.2 
596 Hillman et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
September 1995 
300-  
O 
4.a 
N 200- 
O 
[-~ 
100- 
O 
0 l \ \ \ \ \ l i : : ;~! ' i ,~~;~V/ / / / /~  
0 10 20 40 80 0 
NO (ppm) 
Fig. 1. The effect of inhaled NO on ventilation perfusion 
matching. NO significantly improved ventilation-perfusion 
matching, but no dose-response relationship was note& 
When NO was discontinued, ventilation-peffusion matching 
retumed to baseline levels. *p < 0.05 versus 0 ppm. 
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Fig. 2. NO decreased PA pressure, which returned to 
baseline levels on discontinuation of NO. No dose-re- 
sponse relationship was noted. *p < 0.05 versus 0 ppm. 
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Fig. 3. NO significantly improved transpulmonary vascu- 
lar efficiency (TVE = pulmonary blood flow/total RV 
power). *p < 0.05 versus 0 ppm. 
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Fig. 4. Inhalcd NO resulted in a significant increase in 
Pao 2. When NO was discontinued, Pao 2 returned to 
bascline valucs. *p < 0.05 versus 0 ppm. 
versus 20.5 _ 0.7 mm Hg, p = 0.001) (Fig. 2). NO 
levels greater than 10 ppm did not cause a further 
reduction of PA pressure. NO resulted in a signifi- 
cant decrease in pulmonary vascular resistance; 
however, no significant change in pulmonary blood 
flow occurred (1089 + 72 versus 1026 + 71 ml/min, 
p = 0.38). Characteristic mpedance decreased ur- 
ing NO administration, which indicates an increase 
in the compliance of pulmonary vessels. Total RV 
power and steady power (energy required to move 
blood forward) decreased during NO adminis- 
tration. The absolute value of oscillatory power 
(wasted oscillatory energy during pulsatile blood 
flow) did not change significantly. NO resulted in a 
significant increase in transpulmonary vascular effi- 
ciency (15.4 _+ 0.2 versus 18.2 _+ 0.1 tal/min per 
milliwatt, p = 0.001), indicating more efficient blood 
flow through the pulmonary vascular bed (Fig. 3) 
and improved pulmonary vascular mechanics. 
Effeet of NO on systemie cireulation and oxygen 
delivery. Systemic pressures did not change signifi- 
cantly at any level of NO smdied. Despite an 
increase in Pao 2 (Fig. 4), there was no significant 
change in oxygen delivery (138 _+ 9 versus 141 + 10 
tal/min, p = 0.25) at NO levels of 10, 20, 40, and 80 
ppm. 
Discussion 
Recent studies have identified NO as an impor- 
tant endogenous biologic mediator of vascular tonc, 
platelet function, neurotransmission, i flammation, 
and immune responses. NO is produccd in endothe- 
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lial cells by conversion of 1-arginine to 1-citrulline 
and NO. The reaction is regulated by the enzyme 
NO synthase, located within the endothelial cells, la 
NO freely diffuses to the surrounding tissues includ- 
ing subjacent vascular smooth muscle, where it 
activates the soluble form of guanylate cyclase and 
increases cyclic guanosine 3',5'-monophosphate, 
causing smooth muscle relaxation. 13' 14 Any NO that 
diffuses into the vascular space binds with a high 
affinity to hemoglobin (about 3000 times that of 
oxygen), 15 forming nitrosylhemoglobin andthereby 
becoming inactivated. In the presence of oxygen, 
nitrosylhemoglobin is oxidized to methemoglobin 
and metabolized to nitrites, and nitrates are then 
excreted in the urine, s' 16, 17 Therefore, the high 
affinity of NO to hemoglobin and the rapid inacti- 
vation limits inhaled NO activity to the pulmonary 
vascular bed, resulting in selective pulmonary vaso- 
dilation. 
Ventilation-perfusion mismatch and PA hyper- 
tension are hallmarks of ARDS. Despite improve- 
ments in ventilatory support of patients with ARDS, 
RV failure continues to be responsible for signifi- 
cant morbidity and mortality. 1'2 Acute PA hyperten- 
sion can result in RV dysfunction and subsequent 
cardiac failure. 4Reducing the workload of the RV 
in ARDS may improve RV function and ameliorate 
cardiac failure, is The use of intravenously adminis- 
tered vas0dilators to treat PA hypertension during 
ARDS is !imited because of severe systemic vasodi- 
lation and worsening ventilation-perfusion match- 
ing)9, 20 Because inhaled NO selectively reduces PA 
pressure and improves ventilation-perfusion match- 
ing, NO may provide an important therapeutic strat- 
egy in patients with ARDS. 
Several be, neficial effects of NO in ARDS were 
demonstrOted in our study. Our results support he 
selective pulmonary vasodilatory properties of in- 
haled NO, because minimal systemic effects were 
noted. During the administration of NO, the Pao2/ 
Fi02 rati0, an indication of ventilation-perfusion 
matching, improved significantly. Rossaint and asso- 
ciates 21 110ted similar findings in an uneontrolled 
study of patients with severe respiratory distress. 
The resuRs obtained by Rossaint and colleagues 21
with an inert gas elimination technique suggest 
that NO iincreases Pao  2 by improving ventilation- 
perfusionimatching. Bigatello and coworkers 22 have 
shown that the magnitude of venous admixture at 
baseline correlated with the reduction of venous 
admixture during NO inhalation. NO promotes re- 
gional vaSodilation in ventilated alveoli, which re- 
sults in redistribution of pulmonary blood flow from 
poorly ventilated alveoli to alveoli with improved 
ventilation. The riet result is an increase in the 
Pao2/Fio2 ratio. It has also been shown that exoge- 
nous NO has potent bronchodilator effects in guinea 
pigs with increased airway tone, so that alveolar gas 
exchange is altered. 23 These beneficial effects may 
allow a reduction in Fio2 or positive end-expiratory 
pressure and provide a rationale for the use of NO 
in patients with ARDS. 
Inasmuch as the pulmonary circulation is a highly 
compliant, low-resistance conduit subject o pulsa- 
tile blood flow and under intrinsic, extrinsic, and 
neurohumoral control, conventional steady flow he- 
modynamics do not fully describe the effects of NO 
on the pulmonary vascular bed. Classic pulmonary 
hemodynamic measurements include mean PA 
pressure, PA blood flow, and left atrial pressure or 
pulmonary capillary wedge pressure. Fourier analy- 
sis of pulmonary blood flow and pressure separates 
these measurements into steady and pulsatile com- 
ponents, permitting quantitative descriptions re- 
garding the physical state of the pulmonary vascu- 
lature. 24'2s Characteristic irnpedance, calculated 
from the impedance spectrum, defines the compli- 
ance of the pulmonary vascular bed. The variation 
of characteristic impedänce is inversely proportional 
to the compliance and the cross-sectional area of the 
vascular bed. In contrast to pulmonary vascular 
resistance, which deseribes only steady-state pres- 
sure and flow, characteristic mpedance includes 
the pulsatile components of blood flow and the 
influence of the distal pulmonary vascular bed on 
the proximal vessels. We found a parallel decrease 
in pulmonary vascular esistance and characteris- 
tic impedance with the use of NO. These findings 
suggest that NO results in vasodilation ot only of 
the large vessels of the pulmonary bed but also of 
the small intraparenchymal resistance vessels. 
This supports the use of NO in clinical conditions 
with both large vessel abnormalities (such as in 
patients with congenital heart disease and left-to- 
right shunts) and small vessel abnormalities such 
as ARDS. 
Because the pulmonary vasculature hemodynam- 
ically couples the right and left ventricles, alter- 
ations in the pulmonary circulation can change the 
functional characteristics of the ventricles. There- 
fore the importance of detailed understanding of 
the pulsatile nature of blood flow through the 
pulmonary vascular bed and its relationship to RV 
energy requirements i  underscored. RV hydraulic 
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power is calculated from the impedance spectrum 
and differentiated into components of steady power 
(energy required to move blood forward) plus oscil- 
latory power (wasted energy to move blood in an 
oscillatory fashion). Increased total power results in 
greater RV energy requirements. A disproportion- 
ate increase in the oscillatory component of RV 
power indicates a greater amount of wasted RV 
effort. After lung injury there was a significant 
increase in total RV hydraulic power and a decrease 
in pulmonary blood flow. These findings are related 
to the increased PA pressure caused by lung injury. 
Therefore, lung injury resulted in greater demands 
on the RV (increased RV work) and decreased 
supply (decreased cardiac output). When NO was 
administered there was a reduction in total RV 
power with a concurrent reduction in steady power. 
Transpulmonary vascular efficiency couples RV en- 
ergy requirements with pulmonary blood flow and 
describes how etficiently blood flows through the 
pulmonary vascular bed. Transpulmonary vascular 
efficiency is analogous to supply (pulmonary blood 
flow) and demand (total RV power). Conditions 
that decrease pulmonary blood flow and increase 
RV total power requirements (i.e., acute PA hyper- 
tension) result in a decreased supply and increased 
demand and subsequent cardiac failure. After 
lung injury, pulmonary vasoconstriction developed, 
which resulted in increased RV power and less 
efficient blood flow through the pulmonary vascular 
bed (decreased transpulmonary vascular efficiency). 
During NO administration, pulmonary vasodilation 
occurred and transpulmonary vascular efficiency in- 
creased (because of more etticient pulmonary blood 
flow), which resulted in less RV energy being re- 
quired to maintain blood flow through the pulmo- 
nary vascular bed. These data indicate that NO may 
be beneficial to the RV in ARDS by improving 
pulmonary vascular mechanics and transpulmonary 
vascular etticiency. 
The effects of exogenous NO on oxygen delivery 
are confounding. In acute lung injury the effect of 
exogenous NO on oxygen delivery may be blunted 
when the Sao2 is more than 92%. The reason is that 
an increase in Sao2 more than 92% does not result 
in a significant increase in oxygen content. The lack 
of an increase in oxygen delivery demonstrated in 
our study may be a function of our acute lung injury 
model. In our model, a significant degree of acute 
lung injury was created; however, the Sao 2 was 
maintained at levels greater than 92% and Pao 2 at 
greater than 60 torr at the expense of an increased 
Fio 2, Although NO resulted in a significant increase 
in PaoJFio 2 ratio, demonstrating improved oxygen- 
ation, the Sao 2 and the oxygen content did not 
significantly increase. The beneficial effects of NO 
on improving oxygen content and delivery may be 
more dramatic in conditions in which the Sao2 is less 
tl]an 92%. In these conditions NO administration 
may resutt in a significant increase in Sao 2 and 
oxygen content, leading to an increase in oxygen 
delivery. However, evaluating the success of NO 
in acute lung injury should not be limited to the 
evaluation of NO effects on oxygen delivery. By 
increasing the Pao2/Fioz ratio, administration of 
exogenous NO may allow clinicians to reduce the 
Fio2 required to achieve an acceptable level of 
oxygenation. Thus beneficial effects of NO may be 
appreciated independent of a significant increase in 
oxygen delivery. 
Withdrawal of NO was associated with an in- 
crease in PA pressure to values greater than base- 
line. Early during the study period, seven animals 
died when the NO was precipitously discontinued. 
This effect was due to rebound pulmonary hyper- 
tension and acute nonreversible RV failure. Once 
NO was decreased in a stepwise fashion, rebound 
pulmonary hypertension was no longer problem- 
atic. This result may indicate a down-regulation 
of endogenous NO when exogenous NO is admin- 
istered and is a subject of further studies. One 
limitation of this study is the use of an animal 
model to mimic ARDS. The swine provides a 
stable, reproducible ARDS model. Anatomic vari- 
ations in the swine model have not been shown to 
be prohibitive, and the results from this study 
would not be expected to differ from similar 
studies in human beings. 
Another limitation to the study is the nonrandom- 
ized sequential delivery of NO. Measured differ- 
ences between low NO levels and high NO levels 
may be related to degradation of the preparation 
rather than real differences between the levels of 
NO studied. After data collection at 80 ppm, seven 
animals were returned to 0 ppm NO. There was no 
significant difference between measurements made 
before inhalation of NO and those after NO admin- 
istration. These findings indicate that the measured 
differences were real and not from degradation of 
the preparation. 
Summary 
In our model of ARDS, inhaled NO significantly 
improved pulmonary vascular mechanics, transpul- 
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monary vascular efficiency, and ventilation-perfu- 
sion matching by promoting PA vasodilation. Out 
data suggest hat inhaled NO may be beneficial to 
the RV in ARDS. However, further studies are 
required to determine survival benefit. 
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Discuss ion 
Dr. David A Fullerton (Denver, Colo.). As we all know, 
NO has gained huge notoriety in recent years, and it 
appears to be a valuable agent in patients with acute lung 
injury. In our clinical experience, we have observed that 
when NO works, it works extremely well. We believe it has 
been lifesaving in several patients in our intensive care 
unit. We also have observed that as frequently as it may 
work, it more frequently has little or no effect either on 
decreasing intrapulmonary shunt fraction or improving 
hemodynamics. Studies such as Dr. Fullerton's group has 
presented offer greater insight into when NO may be 
efficacious, when it will not be, and why. 
Dr. Fullerton, can you speculate about some of the 
mechanisms that you believe may be involved in reducing 
the RV inotropic state? You demonstrated substantial 
benefit in reducing RV afterload; however, you para- 
doxically demonstrated that RV inotropy was decreased, 
and you documented that observation with a reduction 
in cardiac output. Unfortunately, the effect on the RV 
negated any potential benefit in systemic oxygen delivery 
and rendered this therapy ineffective. 
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Can you elaborate on what you think may be the 
contributing factor for RV dysfunction in your study? 
Dr. Hillman. NO is involved in multiple pathways in 
the physiologic system. Under conditions of ARDS, 
there is an increase in superoxide free anions. NO, 
combined with these superoxide anions, forms paroxyni- 
trates. Paroxynitrates are a stable molecule but then can 
be transferred to a target organ, that being the myocar- 
dium. Onee in the myocardium, the paroxynitrites can 
dissociate into hydroxyl free radicals and nitrogen dioxide. 
Both of these radicals are highly toxic to the RV and are 
myocardial depressants. NO in association with interleu- 
kin-2 and interleukin-6 have also been shown to be 
myocardial depressants, o that may be another mecha- 
nism. 
Dr. Kent W. Jones (Salt Lake City, Utah). Have you 
used NO concomitantly with an inotropic agent, such as 
dobutamine, that may increase RV function without in- 
creasing pulmonary vascular esistance? 
Dr. Hillman. We have not done that yet, but that is one 
of the hext steps to try with inotropic agents. 
Dr. Davis Drinkwater (LosAngeles, CaIiß). I was struck 
by the fact that you obtained beneficial effeets at such low 
levels of NO in your model. Clinically, we and others have 
been using a dose of 40 to 80 ppm, which, parenthetically, 
I am told is equivalent to the content in the air in the Los 
Angeles basin. I am curious about whether we are over- 
dosing our patients. Clinically, the tank does run out after 
about 12 hours in our experience, and this has significant 
practical implications. Could you comment? 
Dr. Hillman. In most of our studies we did not see much 
benefit with NO concentrations greater than 10 ppm. 
Having noted that, we have started using fewer parts per 
million in more recent studies. We have actually seen 
effects with 1 ppm and have had some clinical experience 
in which 1 ppm was adequate. I think lower dosing is 
probably more appropriate and may avoid the deleterious 
effects of the higher doses.September 1995 
